NeuroSense Therapeutics Ltd. is taking significant steps to enhance its submission for PrimeC, an investigational therapy for amyotrophic lateral sclerosis (ALS). The company announced plans to incorporate newly generated neurofilament light chain (NfL) data into its New Drug Submission (NDS) to Health Canada. This update is crucial as it marks PrimeC's first marketing application in any jurisdiction, potentially addressing the needs of approximately 4,000 Canadians living with ALS.

NeuroSense, a late-stage clinical biotechnology company, focuses on developing treatments for neurodegenerative diseases. The company’s recent filing, dated November 2, 2026, indicates that Health Canada has confirmed a revised filing timeline for March 2027, allowing for the inclusion of additional data that could strengthen the application.

Background

NeuroSense Therapeutics Ltd. is categorized under the SIC code 2834, which pertains to Pharmaceutical Preparations. The company trades on the Nasdaq under the tickers NRSN and NRSNW. It has been actively filing reports, including multiple 6-K forms, with the most recent submissions occurring throughout October and November 2026.

What the Filing Says

The filing states, "Attached is the Company’s press release regarding NeuroSense strengthening of PrimeC Canadian ALS submission with new NfL data." This indicates a strategic move to bolster the application with new scientific evidence that may enhance the chances of regulatory approval.

Impact

This development may significantly affect patients suffering from ALS in Canada, as PrimeC could offer a new treatment option. The company is also in discussions with potential commercialization partners in Canada, which could further facilitate access to this therapy if approved.

What's Next

Following the submission of the NDS, Health Canada’s standard review target is approximately 300 calendar days. If approved, PrimeC would address a notable patient population, with approximately 1,000 new ALS diagnoses each year in Canada. The filing does not specify what happens next beyond the anticipated submission and review process.